A Novel Role of Candesartan and Ramipril in Attenuation of Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection | Chapter 7 | New Horizons in Medicine and Medical Research Vol. 11

 This research looked at how Candesartan and Ramipril affected individuals with chronic hepatitis C's liver fibrosis.

This randomised controlled prospective study included 64 participants with chronic hepatitis C and liver fibrosis. The participants were divided into three groups according to randomization: group I (control group; n=21), which got only conventional therapy; group 2 (Ramipril group; n=21); and group 3 (Candesartan group; n=22); which received just traditional therapy plus 8 mg/day oral Candesartan.

At the beginning, the demographic and laboratory data for the three research groups were statistically identical. In comparison to baseline data, the three research groups' post-treatment liver stiffness, HA and TGF-1 blood levels, and indicators of liver fibrosis all significantly decreased (p 0.001). When compared to the control group six months after therapy, patients taking Ramipril and Candesartan showed a substantial improvement in all analysed parameters. Additionally, the Candesartan group showed a significantly lower level of liver stiffness, biomarkers, and fibrosis indices when compared to the Ramipril group.

Patients with chronic hepatitis C who had liver fibrosis responded well to be successfully treated with ramipril and candesartan. A safe and effective therapy for liver fibrosis in people with chronic liver disease may be candesartan, an AT1-R antagonist that maintained anti-fibrotic action better than Ramipril.

Author(s) Details:

Tarek M. Mostafa,
Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

Gamal A. El-azab,
Department of Clinical Pharmacy, Faculty of Pharmacy, Tanta University, Tanta, Egypt.

Gamal A. Badra,
National Liver Institute, Faculty of Medicine, Menoufia University, Shebin El-kom, Egypt.

Alyaa S. Abdelwahed,
National Liver Institute, Faculty of Medicine, Menoufia University, Shebin El-kom, Egypt.

Abeer A. Elsayed,
Department of Clinical Pharmacy, Faculty of Pharmacy, Sinai University, Al-Arish, Egypt.

Please see the link here: https://stm.bookpi.org/NHMMR-V11/article/view/7142

The Comparative Study Showing of the Effect of Telmisartan and Ramipril on Diabetic Profile in Hypertensive Pre-Diabetic Patients | Chapter 10 | Technological Innovation in Pharmaceutical Research Vol. 8

 Background: Hypertension, a prevalent cardiovascular disease, is rapidly being linked to other co-morbid disorders such as diabetes mellitus, which worsens its prognosis. Telmisartan and ramipril are both antihypertensive medications. The efficacy of telmisartan and ramipril in managing or avoiding the progression of pre-diabetes to diabetes in stage 1 hypertension patients is compared in this study. It also seeks to compare the effects of Telmisartan and Ramipril on FBS and HbA1C in males and females across a 12-month treatment period.

Methods: A 12-month prospective, randomised, single-center, comparative observational study on stage 1 hypertension patients with pre-diabetes is done. A total of 60 individuals are enlisted and assigned to one of two therapy groups. They were given the designated medicine for a 12-month period and were followed up on. Blood pressure was taken and a diabetes profile was checked at each appointment.

The results of this study demonstrated that both telmisartan and ramipril efficiently regulated blood pressure. In stage 1 hypertension individuals with pre diabetes, telmisartan reduced the progression of fasting blood sugar and glycosylated haemoglobin better than ramipril.

Conclusions: Both telmisartan and ramipril had an effect on blood pressure regulation. In stage 1 hypertension patients with pre diabetes, telmisartan has a statistically significant benefit in delaying the progression of prediabetes to diabetes mellitus when compared to ramipril.

Author (s) Details

Abdullah Ansari
Department of Pharmacology, Ayaan Institute of Medical Sciences, Moinabad, Telangana, India.

Ayesha Raoof
Department of Medicine, HAL Medical Centre, Hyderabad, Telangana, India.

View Book :- https://stm.bookpi.org/TIPR-V8/article/view/2213